Members Login
 

The WHO Early Release Guideline on ARV and PrEP

were published on September

30th, 2015 and can be

found here:

 Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

JIAS Special Issue: PrEP Implementation Science: State-of-the-Art and Research Agenda, organized by NEMUS (published July 2015).

 Please visit Nemus´Youtube channell

 

Follow us in Facebook

 

and Twiter

NEMUS Activities 2016

NEMUS Activities 2016



 Jias2016


NEMUS 2nd Special Issue on PrEP in JIAS:

 

 

Global implementation of PrEP as part of combination HIV prevention – Unsolved challenges


Fifteen months after the publication of​ its first supplement on P​re-Exposure Prophylaxis (i.e. PrEP Implementation Science: State-of-the-Art and Research Agenda), NEMUS, in collaboration with UNAIDS, is pleased to share this new collection of contributions focused on PrEP roll-out, identifying barriers and solutions, with a focus on regions and populations not considered before. ​

​The papers included in this new series​ are authored ​by some of the main reseachers, policy makers and advocates who have something valuable to share concerning PrEP today. Together with other tools that will be published soon, such as the upcoming WHO implementation guidelines, this publication will help to document progress and guide implementers through a rapidly changing field.

 

Editorial

No one left behind: how are we doing in the roll-out of PrEP as part of combination HIV prevention? 
Carlos F Cáceres, Linda-Gail Bekker, Peter Godfrey-Faussett

Debate

Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America
Giovanni Ravasi, Beatriz Grinsztejn, Ricardo Baruch, Juan Vicente Guanira, Ricardo Luque, Carlos F Cáceres, Massimo Ghidinelli

Review

The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices
Jae M Sevelius, Madeline B Deutsch, Robert Grant

Research

PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa
Jessica B McGillen, Sarah-Jane Anderson, Timothy B Hallett

Commentary

Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection:
progress and emerging issues in research and policy
Carlos F Cáceres, Annick Borquez, Jeffrey D Klausner, Rachel Baggaley, Chris Beyrer

PrEP implementation research in Africa: what is new?
Frances M Cowan, Sinead Delany-Moretlwe, Eduard J Sanders, Nelly R Mugo,
Fernand Aime Guedou, Michel Alary, Luc Behanzin, Owen Mugurungi, Linda-Gail Bekker

PrEP implementation in the Asia-Pacific region: opportunities, implementation and barriers
Iryna Zablotska, Andrew E Grulich, Nittaya Phanuphak, Tarandeep Anand, Surang Janyam,
Midnight Poonkasetwattana, Rachel Baggaley, Frits van Griensven, Ying-Ru Lo

PrEP in Europe – expectations, opportunities and barriers 
Sheena Mary McCormack, Veronica Noseda, Jean-Michel Molina

Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa
Sybil Hosek, Connie Celum, Craig M Wilson, Bill Kapogiannis, Sinead Delany-Moretlwe, Linda-Gail Bekker

Commentary: the value of PrEP for people who inject drugs 
Rosalind L Coleman, Susie McLean

Viewpoint

PrEP: controversy, agency and ownership 
Gus P Cairns, Kane Race, Pedro Goicochea

 

Share this

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn


Dear colleague:

 

After the completion of important studies providing evidence of the efficacy of PrEP for HIV prevention in various populations, translated into technical recommendations for use by people at increased risk in the context of combination HIV prevention, released by WHO, it is necessary to focus increasingly on tasks that will support countries in assessing the potential role of PrEP in their HIV prevention responses, based on evidence, and eventually help in the roll-out of PrEP as one option for HIV prevention to be used by those who need and want it.

One of those initiatives is the PrEP Task Force in Latin America and the Caribbean, which emerged as a joint initiative of the PAHO HIV Program (through Dr. Giovanni Ravasi) and NEMUS (through Dr. Carlos Cáceres).

At this time, we are pleased to announce the next NEMUS Global Webinar to be focused on:

The PrEP Task Force in Latin America and the Caribbean: A model of technical support for evidence-based HIV PrEP Implementation

 

Giovanni Ravasi

Giovanni Ravasi. is a Medical Doctor, specialized in Infectious Diseases from the Universitá degli Studi of Pavia, Italy, and holds a Master Degree in Public Health from the London School of Hygiene in Tropical Medicine, London, UK. Since 2008 works as Regional Adviser on HIV for the Pan American Health Organization (PAHO), Regional office of the World Health Organization (WHO), based in Brasilia, Brazil, until 2013, and since 2014 in the Regional Headquarter in Washington DC, USA. His main areas of work are HIV drug resistance surveillance, prevention and control, technical cooperation for HIV care and treatment public health policy development, implementation and monitoring and evaluation.

 

Ioannis

Dr. Ioannis (Yannis) Hodges-Mameletzis, WHO. He is an HIV molecular epidemiologist and biologist by training, based in Geneva, Switzerland. He is currently consulting on PrEP at WHO Headquarters and is involved in supporting countries around the technical and programmatic issues around PrEP implementation. He has been extensively involved in the development of evidence-based recommendations for HIV and viral hepatitis at WHO.

 

 

carlosfcaceresp 200

Carlos Cáceres, MD, MPH, PhD. is a Professor of Public Health, and Director of the Center for Interdisciplinary Studies in HIV, AIDS and Society at Cayetano Heredia University (UPCH) in Lima. He is also the Director of the Institute of Studies in Health, Sexuality and Human Development. He obtained his MD degree (1988) from UPCH, and his MPH (1991) and PhD (1996) degrees from UC Berkeley. Throughout the last 20 years he has led numerous studies on HIV/AIDS and sexual health with populations of MSM, transgender women and people living with HIV. He has also conducted extensive research on health policy and systems, focusing on the Global Fund (GFATM) and the National Response to HIV. Apart from his research experience, he has served as a consultant to various UN bodies for diverse planning, research, and training activities. He coordinates the Network for Multidisciplinary studies in ARV-Based HIV Prevention (NEMUS). He was the founder and Past President of the International Association for the Study of Sexuality, Culture and Society, and was a member of the IAS Governing Council (2010-14). In 2014 he was appointed to serve at the Technical Review Panel of the GFATM.

 

The webinar is scheduled to take place on Wednesday 22 March, 2017, at 7:00 am Los Angeles; 8:00 am Mexico; 9:00 Lima, Panama City; 10:00 New York; 11:00 am Brasilia; 2:00 pm London; 3:00 pm Geneva; 4:00 pm Johannesburg; 7.30 pm India, 9:00 pm Bangkok. To check the time in your specific time zone, please visit:

http://www.worldtimeserver.com/meeting-planner.aspx

To register for the webinar please click on the following link:

 

https://goo.gl/forms/lKPJGIuYRCkWxUv42

 

After you register you will receive a confirmation e-mail with instructions to access the webinar and background readings.Looking forward to your participation. 

 

Share this

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn


Estimadas y estimados colegas:

 

Reciban un saludo por el inicio de este año 2017, cuyo primer mes ha pasado muy rápidamente​. ​Son tiempos en que las discusiones sobre la implementación de PrEP van haciéndose más frecuentes y sostenidas en la región, con planes ​​crecientes de estudios complementarios que permitan obtener mayor evidencia para decidir su inclusión en la respuesta programática, o para adaptarlo al sistema de salud de países determinados. Por ello, ​continuaremos con la presentación de experiencias de interés, o resultados de investigaciones relevantes. En ese sentido, ​el proximo jueves​ ​2 de Febrero,​​ el Dr.​ ​Hamid Vega y el ​Lic. Steven Díaz de las Clinicas Especializadas Condesa-Iztapalapa de la Ciudad de México,​ nos presentará​​n:

 

"Situación y Perspectivas del Acceso a PrEP para la Prevención del VIH en México"

 

Hamid Vega

Hamid Vega es médico psiquiatra egresado del Instituto Nacional de Psiquiatría “Ramón de la Fuente Muñiz”. Doctorante en Salud Mental Pública por la UNAM. Coordinador del Programa de Salud Mental de la Clínicas Especializadas Condesa y Condesa-Iztapalapa. Es miembro del Comité Técnico Consultivo sobre VIH e ITS de la OPS. Junto con su equipo, se encargan de la atención clínica e investigación de los trastornos mentales en las personas con VIH y otras minorías sexuales.

 

Steven Diego

Steven Diego estudió Psicología y Matemáticas en la Universidad del Estado de Illinois. También tiene formación en Promoción y Educación en Salud Pública. Tiene más de 30 diplomados en temas de enfermedades infecciosas (incluyendo VIH) en E.U.A. y Latinoamérica. Su experiencia en VIH, tanto en prevención como en provisión de servicios, ha sido desarrollada en Estados Unidos, México, Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panamá, Perú, Ecuador, Brasil, Argentina y Chile. Actualmente es el Subdirector de Prevención e Información para el Centro para la prevención Integral del VIH/sida de la Ciudad de México.

 

El webinar se desarrollará el Jueves 02 de Febrero de 2017 a las ​7​:00 am en Los Angeles, 9:00am en C. de ​México, C. de ​Guatemala, y San José; 10.00am en ​Nueva York, ​Lima​, Bogotá​, Quito​, ​​C. de Panamá​ y Washington​; ​1​2m ​en ​Buenos Aires​ y Santiago​; 1:00pm en ​Rio de Janeiro y ​Brasilia, ​3​:00pm en Lisboa y Londres; y ​4​pm en Madrid y París. Para otros países/ciudades, por favor visite:

 

http://www.worldtimeserver.com/meeting-planner.aspx

 

Para registrarse para el webinar, por favor ingrese en:

 

https://goo.gl/forms/fewkFsAplFqzVbZv1

 

Luego de registrarse recibirá un mensaje confirmatorio con instrucciones para ingresar al webinar vía gotomeeting, y lecturas de apoyo. Esperamos contar con su participación.

 

 

 

Share this

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn


Dear colleague:

 

On occasion of World AIDS Day 2016, NEMUS is pleased to offer a Special Program of 3 presentation of its Global Webinar Series: the third On Monday, 5 December, Jerome Galea, PhD, who is in charge of the PrEP in the Wild Study of individual/community led access to PrEP, will present on

PrEP in the Wild - An interim Analysis
(05 December)

Jerome Galea

Jerome Galea is the Deputy Director of Partners in Health and the co-founder of the LGTB Epicenter community center, both organizations in Lima, Peru, and a postdoctoral Fellow at the Harvard Medical School. He has studied and published on the acceptability of PrEP in Peru and is currently investigating the informal use of PrEP in the Wild PrEP study.

To register for the webinar please click on the following link:

 

https://goo.gl/forms/0xsEvSQuFL8BHflE2

 

After you register you will receive a confirmation e-mail with instructions to access the webinar and background readings.Looking forward to your participation. 

 

Share this

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn


Dear colleague:

 

On occasion of World AIDS Day 2016, NEMUS is pleased to offer a Special Program of 3 presentation of its Global Webinar Series: the second on Monday 28 November, Raphael Landovitz, MD, who was one of the Lead Rapporteurs at the recent R4P Conference, will present on 

 

ARV-based prevention and PrEP research - News from the 2016 Research for Prevention Conference
(28 November)

Rafael Landovitz

Raphael J Landovitz´s clinical research career focuses on optimizing the use of HIV antiretroviral therapy for both HIV treatment and HIV prevention.
Dr. Landovitz was trained at Princeton University and Harvard Medical School. He completed post-graduate training in internal medicine at Brigham and Women’s Hospital (1996-1999) and Infectious Diseases and HIV Medicine at Brigham and Women’s Hospital and Massachusetts General Hospital (1999-2001). The served as Chief Medical Resident at the Brigham and Women’s Hospital from 2001-2002. He served on the faculty of the Division of Infectious Diseases at the Brigham and Women’s Hospital from 2001-2005, and then as Medical Co-Director of the Vietnam CDC-Harvard Medical School AIDS Partnership. He is Currently Associate Professor of Medicine in the Division of Infectious Diseases at UCLA, Associate Director of the UCLA Center for Clinical AIDS Research & Education, and Co-Director of the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS). He is leading the NIH/DAIDS funded Phase 2a and Phase 3 studies of long-acting injectable PrEP using cabotegravir (GSK 1265744). He was awarded the John Carey Young Investigator Award by the AIDS Clinical Trials Group in 2010..

 

 

Share this

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn


Dear colleague:

 

On occasion of World AIDS Day 2016, NEMUS is pleased to offer a Special Program of 3 presentation of its Global Webinar Series, the first one On Tuesday 22 November, Sybil Hosek, PhD and Alejandra Trossero, MA, will present on an increasingly important topic globally:

 

PrEP and Adolescents at Risk: Existing Evidence and Plans for a Demonstration Study
(22 November)

sibil hosek

Sybil Hosek is a Clinical Psychologist/HIV Researcher at Stroger Hospital of Cook County with over 15 years experience in the development and implementation of HIV-related research studies and behavioral interventions. Her current research focuses on biomedical primary prevention interventions, for adolescents and young adults, including PrEP and microbicides, and the development of behavioral interventions to improve uptake and adherence to these new biomedical strategies. Dr. Hosek is currently vice-chair of the IMPAACT Prevention Scientific Committee, a member of the HPTN Adolescents At Risk Scientific Committee, and co-chair of the HANC Youth Prevention Research Working Group.

 

Alejandra Trossero

Alejandra Trossero recently joined UNICEF Latin American and the Caribbean Regional office as the Regional Adolescent and HIV/AIDS Specialist. Alejandra has over 18 years of experience working on HIV and sexual and reproductive health (SRH). Prior to joining UNICEF, she hold positions at UNDP and the International Planned Parenthood Federation (IPPF), focusing on HIV and SRH integration, establishing a 5-year research program in three Sub-Saharan Africa countries to assess the efficacy and cost-benefit of integrating HIV and SRH services – with Population Council and London School of Hygiene and Tropical Medicine. She is currently serving as the Chair of the Program Advisory Panel at the Robert Carr Civil Society Network Fund. Alejandra, who hails from Argentina, has a degree in Psychology and a Masters in Science in Reproductive and Sexual Health Research from the London School of Hygiene and Tropical Medicine.

 

 

Share this

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn


Page 1 of 4